DEVELOPMENTAL FUNDS

项目总结(见说明)： 在过去的五年里。发展资金已用于支持试点项目、招募新的研究人员和开发新的核心设施，以促进UCCCC的战略目标，包括扩大人口和转化研究、免疫疗法以及跨学科和跨计划的合作。从2008-2012年，CCSG投资1,519,611美元，在同行审查支助以及出版物和方案开发方面产生了33,870,022美元的显著回报。对10名新研究人员的支持有助于加强癌症、造血和血液系统恶性肿瘤的分子机制、药物基因组学和实验治疗以及癌症预防和控制计划。除了一个例外，所有这些教职员工都留在了该机构，都是UCCCC的活跃成员。重要招聘的例子包括：Tina Shih博士，癌症经济学家，在CPC计划中领导癌症经济学的发展；陈建军博士，他在白血病和淋巴瘤的遗传和表观遗传改变方面的研究加强了HHM计划；Peter O‘Donnell医学博士，他正在应用他在药物基因组学及其应用方面的专业知识来领导1200名患者的试验。CCSG发展基金支持了四个新开发的核心设施：流行病学和研究招募核心(ERRC)、人类成像研究办公室(HIRO)、代谢组学和生物流体股，后者现在是药理学核心设施的完整组成部分。此外，生物统计核心设施增加了独特的生物信息学服务(下一代测序信息学)，现已纳入机构生物信息学核心(UCCCC正在开发的核心)。发展中的核心继续增长，并为跨学科合作和翻译研究做出了重大贡献。 在下一个赠款期间，我们要求每年提供360,000美元，用于：1)招募新的调查人员(12万美元)；2)计划开发/计划试点项目(14万美元)；以及3)开发新的核心设施(10万美元)。这些资金将用于推进我们战略计划的三个组成部分：1)个性化癌症护理联盟(PCCC)；2)癌症预防和人口医学中心；以及3)癌症生存、癌症经济学和结果计划。我们将在下一个CCSG周期的最初几年支持ERRC、HIRO、生物信息学和新陈代谢学开发核心。预计随着对其他新技术的需求的确定，CCSG发展基金将用于这些新技术的开发。

PROJECT SUMMARY (See instructions): Over the past five years. Developmental Funds have been used to support Pilot Projects, recruitment of new Investigators, and development of new Core Facilities to further UCCCC strategic goals, including expansion of population and translational research, immunotherapy, and interdisciplinary and interprogrammatic collaborations. From 2008-2012, a CCSG Investment of $1,519,611 has yielded a remarkable return of $33,870,022 In peer-reviewed support, as well as publications and programmatic development. Support for 10 new investigators has contributed to enhancements in the Molecular Mechanisms of Cancer, Hematopoiesis and Hematological Malignancies, Pharmacogenomics and Experimental Therapeutics and Cancer Prevention and Control Programs. With one exception, all of these faculty have remained at the institution and are active members of the UCCCC. Examples of significant recruitments include: Tina Shih, PhD, a cancer economist who is leading the development of cancer economics in the CPC Program; Jianjun Chen, PhD, whose research in genetic and epigenetic alterations in leukemia and lymphoma strengthens the HHM Program, and Peter O'Donnell, MD, who is applying his expertise in pharmacogenomics and its application to lead the 1200 Patient Trial. Four new developing Core Facilities were supported with CCSG developmental funds: Epidemiology and Research Recruitment Core (ERRC), Human Imaging Research Office (HIRO), Metabolomics, and the Biofluids Unit, the latter now a full component of the Pharmacology Core Facility. In addition, unique bioinformatics services (next-generation sequencing informatics) were added to the Biostatistics Core Facility, and have now been integrated into the institutional Bioinformatics Core (a developing UCCCC core). The developing cores continue to grow and have significantly contributed to interdisciplinary collaborations and translational research. Over the next grant period, we are requesting $360,000/year for: 1) recruitment of new investigators ($120K); 2) Program development/Program Pilot Projects ($140K); and 3) development of new Core Facilities ($100K). These funds will be used to further the three components of our Strategic Plan: 1) the Personalized Cancer Care Consortium (PCCC); 2) the Center for Cancer Prevention and Population Medicine; and 3) the Program in Cancer Survivorship, Cancer Economics, and Outcomes. We will support the ERRC, HIRO, Bioinformatics, and Metabolomics developing cores in the initial years of the next CCSG cycle. It is anticipated that as the needs for other new technologies are identified, CCSG developmental funds will be applied to their development.